Clinical Trials Logo

Anxiety Disorders clinical trials

View clinical trials related to Anxiety Disorders.

Filter by:

NCT ID: NCT04569760 Withdrawn - Clinical trials for Generalized Anxiety Disorder

Cannabinoids for the Treatment of Anxiety Disorders: An 8-Week Pilot Study

Start date: April 2021
Phase: Phase 3
Study type: Interventional

This proposed study aims to evaluate the efficacy of a daily oral cannabinoid oil preparation in treating symptoms of DSM-5 anxiety disorders, using a two-arm, 8-week randomized, placebo-controlled trial in adults aged 21-65 years. The study will also evaluate the relationship between inflammation, anxiety and cannabinoids using biological markers as well as examine the neuro-cognitive effects of cannabinoid treatment.

NCT ID: NCT04287452 Withdrawn - Chronic Pain Clinical Trials

Canine-Assisted ANxiety Reduction IN Emergency Care IV

CANINE IV
Start date: March 1, 2022
Phase: N/A
Study type: Interventional

Prior literature demonstrates that human stress can be reduced with exposure to animals. This study challenges current dogma by introducing a widely available, low cost method of dog therapy to reduce patient and provider stress. The objectives of this study are to determine if interaction with a certified therapy dog and handler can; - decrease reported anxiety levels in emergency department (ED) patients, - decrease salivary cortisol in ED patients, - decrease total morphine equivalent dosing in the emergency department or at discharge and/or, - decrease reported stress levels in emergency department providers caring for participating patients when compared to usual care.

NCT ID: NCT04267679 Withdrawn - Anxiety Clinical Trials

Cannabidiol for Anxiety

Start date: March 1, 2020
Phase: Phase 2
Study type: Interventional

This pilot trial seeks to investigate the effect of 25 mg full-spectrum CBD soft gel capsules (up to a total dosage of 100mg per day) on individuals with diagnosed anxiety. All participants will take CBD soft gel capsules for 12 weeks, and will be assessed at 6 weeks and 12 weeks post-enrollment using measures of anxiety, sleep and perception of change.

NCT ID: NCT04260776 Withdrawn - Clinical trials for Tobacco Use Disorder

Adaptive Treatment Strategies for Improving Engagement With a Web-Based Smoking Intervention in Socially Anxious Smokers

Start date: April 15, 2022
Phase: Phase 1
Study type: Interventional

This phase I trial will use a pilot sequential multiple assignment randomized trial (SMART) to examine protocol feasibility and acceptability of new components of a web-based intervention for socially anxious smokers. This study will be used to help build an adaptive treatment strategy to improve engagement with and effectiveness of the web-based intervention. Adaptive treatment strategies provide individualized sequences of intervention components to accommodate the changing needs of individuals based on their characteristics, treatment response, or engagement.

NCT ID: NCT04172909 Withdrawn - Anxiety Clinical Trials

LEGO MRI: Decreasing the Need for Sedation, and Improving Patient Anxiety.

LEGO MRI
Start date: February 24, 2020
Phase: N/A
Study type: Interventional

The objective of the LEGO®Bricks MRI project is to study a new play-based tool for use in children preparing to undergo MRI and evaluate its ability to reduce the need for anesthesia. A randomized study design will be employed in the experimental "Child Life" (CL) group, in regard to which Child Life intervention patients will have. Age matched controls will be found retrospectively, and will be patients of the same age, undergoing their first non-contrast brain MRI with no Child Life intervention. Patients in the CL group will be prepped by a Certified Child Life Specialist with the use of one of the following 2 tools, to be randomly selected: 1. LEGO Bricks model MRI (A model of the MRI machine and adjacent control room made out of LEGO bricks) 2. Mock MRI tube (A six foot long pop-out play tunnel for children, with a diameter of around 17 inches to simulate the MRI magnet bore)

NCT ID: NCT04086342 Withdrawn - Clinical trials for Social Anxiety Disorder

CHI-902 for Treatment of Social Anxiety Disorder

Start date: January 24, 2020
Phase: Phase 2
Study type: Interventional

No substantial clinical trials of Cannabidiol (CBD) in Social Anxiety Disorder (SAD) have yet been conducted. This randomized doubleblind, placebo-controlled trial of CBD in adults with SAD will evaluate the efficacy, tolerability and safety of CBD oil (CHI-902) in SAD. In addition, the effects of treatment with CHI-902 on the Endocannabinoid System (ECS) will be assessed by evaluating peripheral endocannabinoids (Arachidonoylethanolamide/Anandamide (AEA) and 2-Arachidonoyl glycerol (2-AG)) before and after treatment.

NCT ID: NCT03924908 Withdrawn - Anxiety Clinical Trials

Impact of Virtual Reality Hypnosis on Pain and Anxiety During Dressings Change in Burn Patients

Start date: January 1, 2023
Phase: N/A
Study type: Interventional

Different non-pharmacological techniques, including hypnosis and virtual reality are currently used as complementary tools in the treatment of pain related to burn injury. A new technique called 'virtual reality hypnosis' (VRH) (Patterson et al., 2004), which encompasses a combination of both tools, is regularly used although its actual function remains unknown to this date. With the goal to improve our understanding of VRH combination effects, it is necessary to elaborate randomized and controlled research studies in order to understand their actual function in individual's perception. 100 patients who are treated as outpatients for burn care will be randomly assigned to virtual reality or VRH. Patients will receive one session of one of these techniques during burn dressing change.Physiological parameters will be recorded during dressing change. Participants will fill in a questionnaire evaluating their tendency to be absorbed and dissociated, and another evaluating their level of perceived immersion. Their level of anxiety, pain, fatigue and relaxation will be evaluated before and after the session. A short interview will also be conducted to give participants the opportunity to openly describe their experience.

NCT ID: NCT03769363 Withdrawn - Clinical trials for Social Anxiety Disorder

Waitlist-Control Trial of Smartphone CBT for Social Anxiety Disorder (SAD)

Start date: July 1, 2019
Phase: N/A
Study type: Interventional

The investigators are testing the efficacy of Smartphone-delivered cognitive behavioral therapy (CBT) treatment for social anxiety disorder (SAD). The investigators hypothesize that participants receiving app-CBT will have greater reduction in LSAS scores than those in the waitlist condition at treatment endpoint (week 12).

NCT ID: NCT03522987 Withdrawn - Depression Clinical Trials

Anxiety and Depression in Epilepsy: A Pilot Treatment Study

Start date: May 2018
Phase: Phase 4
Study type: Interventional

As a potential solution to address high rates of depression and anxiety seen in epilepsy patients and poor mental health care access, this trial aims to carry out treatment for depression and anxiety directly in the epilepsy clinic. Patients that meet eligibility criteria, including significant symptoms of depression and/or anxiety, will be enrolled in the intervention. The intervention will consist of an initial prescription for an FDA-approved medication to treat depression/anxiety and telephone-based chronic care management plan for repeated symptom measurement and side effect surveillance. The purpose of this pre-piloting limited study is to streamline recruitment, intervention and outcome assessment process in preparation for a randomized, controlled pilot of the intervention.

NCT ID: NCT03490903 Withdrawn - Clinical trials for Coronary Artery Disease

Coronary Angiography THerapeutic Virtual Reality

CATH-VR
Start date: June 1, 2018
Phase: N/A
Study type: Interventional

The CATH-VR study will investigate the effect of virtual reality (VR) on patient pain, anxiety, and radial artery vasospasm during coronary angiography. Our hypothesis is that the use of VR will decrease patient anxiety and pain via validated scoring systems, as well as show a low rate of vasospasm of the radial artery. In addition, we hypothesize that the amount of opioid and benzodiazepine medications utilized for procedural sedation will be lower in the intervention arm. VR has gained recent attraction as an alternative or adjunctive treatment option for pain, but its effect on reducing procedural sedation has not been studied. We propose a single center, randomized control pilot study to further investigate. The patient population will include adults older than 18 years who present for outpatient diagnostic coronary angiography.